Andrea Tan
Stock Analyst at Goldman Sachs
(1.69)
# 3,324
Out of 5,182 analysts
53
Total ratings
39.02%
Success rate
-2.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrea Tan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KRYS Krystal Biotech | Maintains: Buy | $206 → $327 | $260.95 | +25.31% | 2 | Feb 2, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Neutral | $50 → $85 | $61.03 | +39.28% | 3 | Jan 7, 2026 | |
| INSM Insmed | Maintains: Buy | $258 → $225 | $162.43 | +38.52% | 15 | Dec 18, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Buy | $16 → $8 | $3.43 | +133.24% | 7 | May 12, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Neutral | $46 → $51 | $70.12 | -27.27% | 4 | May 5, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Buy | $39 → $27 | $21.45 | +25.87% | 6 | Mar 25, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Neutral | $23 → $6 | $5.32 | +12.78% | 5 | Jul 1, 2024 | |
| RLMD Relmada Therapeutics | Downgrades: Sell | $3 → $2 | $6.99 | -71.39% | 3 | Jun 5, 2024 | |
| KOD Kodiak Sciences | Reinstates: Sell | $2 | $40.63 | -95.08% | 1 | Dec 11, 2023 | |
| ABCL AbCellera Biologics | Maintains: Buy | $27 → $24 | $3.52 | +581.82% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $10 → $4 | $1.22 | +227.87% | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $375 | $546.89 | -31.43% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $120 → $80 | $18.05 | +343.21% | 2 | May 24, 2022 |
Krystal Biotech
Feb 2, 2026
Maintains: Buy
Price Target: $206 → $327
Current: $260.95
Upside: +25.31%
Arrowhead Pharmaceuticals
Jan 7, 2026
Maintains: Neutral
Price Target: $50 → $85
Current: $61.03
Upside: +39.28%
Insmed
Dec 18, 2025
Maintains: Buy
Price Target: $258 → $225
Current: $162.43
Upside: +38.52%
Iovance Biotherapeutics
May 12, 2025
Maintains: Buy
Price Target: $16 → $8
Current: $3.43
Upside: +133.24%
Tarsus Pharmaceuticals
May 5, 2025
Maintains: Neutral
Price Target: $46 → $51
Current: $70.12
Upside: -27.27%
Day One Biopharmaceuticals
Mar 25, 2025
Maintains: Buy
Price Target: $39 → $27
Current: $21.45
Upside: +25.87%
Sagimet Biosciences
Jul 1, 2024
Maintains: Neutral
Price Target: $23 → $6
Current: $5.32
Upside: +12.78%
Relmada Therapeutics
Jun 5, 2024
Downgrades: Sell
Price Target: $3 → $2
Current: $6.99
Upside: -71.39%
Kodiak Sciences
Dec 11, 2023
Reinstates: Sell
Price Target: $2
Current: $40.63
Upside: -95.08%
AbCellera Biologics
Aug 4, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $3.52
Upside: +581.82%
Jan 9, 2023
Maintains: Sell
Price Target: $10 → $4
Current: $1.22
Upside: +227.87%
Dec 20, 2022
Maintains: Buy
Price Target: $178 → $375
Current: $546.89
Upside: -31.43%
May 24, 2022
Maintains: Neutral
Price Target: $120 → $80
Current: $18.05
Upside: +343.21%